Insider Buying: Cyclopharm Limited (ASX:CYC) Insider Purchases A$13,800.00 in Stock

Cyclopharm Limited (ASX:CYCGet Rating) insider Kevin Barrow purchased 10,000 shares of Cyclopharm stock in a transaction on Friday, December 2nd. The shares were acquired at an average cost of A$1.38 ($0.93) per share, for a total transaction of A$13,800.00 ($9,261.74).

Cyclopharm Stock Performance

The company has a debt-to-equity ratio of 10.92, a quick ratio of 4.68 and a current ratio of 5.53.

About Cyclopharm

(Get Rating)

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism.

Read More

Receive News & Ratings for Cyclopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclopharm and related companies with MarketBeat.com's FREE daily email newsletter.